SCHEMBL7936587

SCHEMBL7936587

CC(C)CCCCNC(=O)CN

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GNAI3 P08754 1/20 0.40
GNAO1 P09471 1/20 0.40
GNAI1 P63096 1/20 0.40
HPGD P15428 2/20 0.40
DPP7 Q9UHL4 2/20 0.40
ANPEP P15144 2/20 0.40
DNPEP Q9ULA0 1/20 0.40
TP53 P04637 1/20 0.40
PAOX Q6QHF9 2/20 0.39
RRM1 P23921 1/20 0.39
CASP2 P42575 1/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
EPHX1 P07099 1/20 0.38
RNPEP Q9H4A4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7947948 0.94 KMT2A (0.41) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL7944266 0.85 ANPEP (0.52) ALDH1A1SMN1; SMN2HPGDANPEPDNPEP
SCHEMBL29300401 0.85 LMNA (0.46) KMT2AMEN1ALDH1A1GNAI3GNAO1
SCHEMBL14682812 0.84 KMT2A (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL18313728 0.83 ALDH1A1 (0.52) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD
SCHEMBL29237467 0.83 CASP2 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2GNAI3
SCHEMBL20813199 0.83 HPGD (0.54) ALDH1A1HPGDANPEPDNPEPCASP2
SCHEMBL16853212 0.82 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1SMN1; SMN2PAOX
SCHEMBL17740189 0.82 SLC6A5 (0.55) ALDH1A1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL24692521 0.82 SMN1; SMN2 (0.58) KMT2AMEN1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584748-B2 Spirocyclic compounds C4 THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-20210032245-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2021-02-04 US disclosed
US-20100003276-A1 Methods for treating anthrax and inhibiting lethal factor HERMES JEFFERY D 2010-01-07 US disclosed
US-7504425-B2 Compounds useful in the treatment of anthrax and inhibiting lethal factor MERCK & CO., INC. (US) 2009-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003276-A1 Methods for treating anthrax and inhibiting lethal factor ANTXR2, SERPINB1, APAF1 KMT2A 4071/4885MEN1 2618/4885ALDH1A1 4088/4885
US-20210032245-A1 SPIROCYCLIC COMPOUNDS CRBN, RBX1, XIAP KMT2A 1849/4885MEN1 1561/4885ALDH1A1 2000/4885
US-11584748-B2 Spirocyclic compounds CRBN, RBX1, XIAP KMT2A 1849/4885MEN1 1561/4885ALDH1A1 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.